A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Icotinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 12 Jul 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.